Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Heildartekjur ársins 2022 hækkuðu um 114% í 85,0 milljónir dollara samanborið við 39,7 milljónir dollara á árinu 2021, vegna tekna af sölu AVT02, líftæknihliðstæðu við Humira®, sem komin er á markað í...
-
Full year 2022 total revenue, including other income, increased by 114% to $85.0 million, compared to $39.7 million in 2021, driven by both milestone revenue and product revenue from commercialization...
-
Full year 2022 total revenue, including other income, increased by 114% to $85.0 million, compared to $39.7 million in 2021, driven by both milestone revenue and product revenue from commercialization...
-
REYKJAVIK, Iceland, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide,...
-
Alvotech (NASDAQ: ALVO) mun birta fjárhagsuppgjör ársins 2022 eftir lokun markaða í Bandaríkjunum, miðvikudaginn 1. mars 2023. Þá mun Alvotech halda kynningarfund fyrir fjárfesta fimmtudaginn 2. mars...
-
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results...
-
Alvotech (NASDAQ: ALVO) tilkynnti í dag að samningur við Landsbankann hf. um viðskiptavakt á hlutabréfum Alvotech hafi verið uppfærður, en Landsbankinn hefur séð um viðskiptavakt á hlutabréfunum síðan...
-
Alvotech (Nasdaq: ALVO) and Landsbankinn hf. have updated their market making agreement, which has been in effect since Alvotech’s shares were admitted to trading in Iceland on June 23, 2022. The...
-
Alvotech (NASDAQ: ALVO) tilkynnti í dag að uppgjöri viðskipta í lokuðu hlutafjárútboði sem tilkynnt var um 23. janúar sl. væri nú lokið. Alls hafa 11.834.061 hlutabréf í Alvotech sem áður voru í eigu...
-
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today the completion of the equity...